Lifestyle
- Regular moderate exercise
- Stress management techniques
- Adequate sleep
Interleukin-6 · Interleukin 6
IL-6 quantifies the concentration of interleukin-6, a cytokine involved in inflammatory and immune responses.
Levels can vary with age and are influenced by circadian rhythms.
Interleukin-6 (IL-6) is a multifunctional cytokine involved in the regulation of immune responses, inflammation, and hematopoiesis. It is produced by various cells, including leukocytes, adipocytes, and endothelial cells, and plays a critical role in the body's defense mechanisms. IL-6 is known to mediate the acute phase response, stimulating the production of C-reactive protein (CRP) by the liver. Clinically, IL-6 is a significant biomarker for inflammatory conditions and is associated with cardiovascular diseases, such as atherosclerosis and cardiogenic shock, as well as other conditions like amyotrophic lateral sclerosis (ALS). Elevated levels of IL-6 are indicative of systemic inflammation and have been linked to poor outcomes in acute cardiac events. In the context of athletic performance and biohacking, IL-6 is of interest due to its role in muscle repair and adaptation to exercise, though chronic elevation may indicate overtraining or systemic inflammation. Researchers have observed that IL-6 levels can be influenced by factors such as age, time of day, and acute stressors, making it important to consider these variables when interpreting test results. Diurnal variation and the impact of recent physical activity are notable confounders that can affect IL-6 levels, necessitating standardized testing conditions for accurate assessment.
Klinische Bedeutung
Elevated IL-6 levels indicate systemic inflammation and are associated with conditions such as cardiovascular disease, infection, and autoimmune disorders. Reduced IL-6 levels are less commonly discussed but may suggest impaired immune response.
Progressively rising IL-6 values suggest worsening inflammation or disease progression. Retest in 4-6 weeks.
Falling IL-6 values may indicate a response to treatment or resolution of inflammation.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplement regimen.
IL-6 levels may vary throughout the day; morning samples are preferred for consistency.
Testing Frequency
Frequency depends on clinical context; consult healthcare provider.
Correlated with
Current research suggests that the perioperative kinetics of IL-6 in cardiac surgical patients and its precise role as a prognostic biomarker in cardiogenic shock remain insufficiently understood. Researchers have not yet established definitive reference ranges for IL-6 in various clinical contexts, nor have they clarified the confounding effects of age and respiratory dysfunction on IL-6 levels in conditions like amyotrophic lateral sclerosis. Unanswered clinical questions include the optimal therapeutic targets for IL-6 inhibition in diverse cardiovascular diseases.
998
Total Citations
6
Human/RCT
4.3
Avg. Influence
2025
Latest
This review examined the role of IL-6 in cardiovascular disease and its potential as a biomarker for vascular risk. Researchers found that IL-6 signaling is involved in atherogenesis and may serve as a target for therapeutic intervention. Additionally, the study highlighted the development of ziltivekimab, an IL-6 ligand inhibitor, for use in patients with chronic kidney disease.
This study explored the significance of C-reactive protein (CRP), which is influenced by IL-6, as a marker of inflammation in clinical settings. Researchers found that CRP is widely requested in laboratories due to its sensitivity in diagnosing various inflammatory conditions. The study also noted the renewed interest in CRP as a biomarker for COVID-19 severity.
This study highlighted the significance of IL-6 in Castleman disease, particularly its plasma cell variant. Researchers found that IL-6 is central to the disease's pathogenesis and that treatments targeting IL-6, such as tocilizumab, have shown improvement in symptoms. The study underscores IL-6's role in the clinical management of this condition.
Researchers conducted a systematic review on interleukin-6 (IL-6) as a prognostic biomarker in traumatic brain injury (TBI). They found that elevated IL-6 levels were associated with poorer clinical outcomes, although results varied across studies.
This review summarized the role of IL-6 in neurodegenerative disorders, noting its involvement in neuroinflammation. Researchers found that high IL-6 levels are associated with disease progression and may serve as a biomarker for these conditions. The study calls for further exploration of IL-6's clinical applications in neurodegenerative diseases.
This study investigated IL-6 levels in patients with amyotrophic lateral sclerosis (ALS) compared to healthy controls. Researchers found that while IL-6 levels were elevated in ALS patients, variability was significant and correlated with respiratory dysfunction. The study indicated that aging also influences IL-6 levels in healthy individuals.
This article explored the role of IL-6 in ischemic stroke, a condition characterized by inflammation and oxidative stress. Researchers found that IL-6 is a key inflammatory mediator during the acute phase of stroke and may serve as a prognostic factor for patient outcomes. The study emphasizes the importance of IL-6 in stroke pathophysiology.
This study investigated the relationship between lipoprotein(a) [Lp(a)] and interleukin-6 (IL-6) in the context of atherosclerotic cardiovascular disease (ASCVD). Researchers found that IL-6 receptor inhibitors can lower Lp(a) levels and may have dual effects on inflammation and apolipoprotein synthesis, suggesting potential benefits in ASCVD prevention. The study calls for more trials to clarify these interactions.
This review explored the role of interleukin-6 (IL-6) in rheumatoid arthritis (RA) treatment. Researchers found that IL-6 inhibition shows superior efficacy compared to placebo and traditional therapies, with a comparable safety profile to TNF inhibitors. The findings highlight the importance of targeting IL-6 in managing RA.
This study focused on the immunopathogenesis of neuromyelitis optica (NMO) and the role of interleukin-6 (IL-6) receptor signaling in its treatment. Researchers found that therapies targeting IL-6 receptor are effective in preventing NMO relapses, suggesting IL-6 as a potential biomarker for treatment responsiveness. The findings support a precision medicine approach in NMO management.
1
Total Trials
36
Total Enrolled
Utah State University
36
2023
Inflammatory cytokine biomarker (IL-6) concentrations in plasma samples
Research publications about IL-6 over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer